Welcome to Arizona’s Bioscience Roadmap, a long-term strategic plan originally commissioned by the Flinn Foundation in 2002 and updated in 2014 with the goal of Arizona becoming globally competitive and a national leader in select areas of the biosciences by 2025.
2. Turning research into practice;
3. Developing bio-talent;
4. Promoting Arizona’s convergence of research, health care, and commercialization to economic partners in neighboring states, Canada, and Mexico; and
5. Enhancing the state’s “collaborative gene” reputation.
The Roadmap is guided by Arizona’s Bioscience Roadmap Steering Committee, a group of about 135 state leaders from the private and public sectors in science, health care, business, academia, and policy.
The Roadmap was compiled by the Battelle Technology Partnership Practice based on research and input from Arizona leaders as well as national bioscience experts. Battelle produced a comprehensive study released in 2002 that found Arizona possessed many of the essential elements needed to become a global leader in niche areas in the biosciences, but must strengthen its biomedical-research base and build a critical mass of bioscience firms and jobs.
The Flinn Foundation has commissioned Battelle, followed by TEConomy Partners, since the inception of Arizona’s Bioscience Roadmap to track progress on performance measures involving the state’s bioscience sector.
The data pertaining to a consistent set of metrics, including jobs, wages, capital, research and development, and technology transfer, is gathered and reported publicly on a biennial basis.
In addition, the Flinn Foundation tracks the progress of the bioscience sector each year by highlighting the state’s major developments.
The latest Progress Report released in April 2023 highlights the key bioscience advances from 2022 and what lies ahead as new investments in fields like semiconductors supercharge Arizona—and the biosciences. The foundation’s annual event featured Arizona Gov. Katie Hobbs, mayors Kate Gallego of Phoenix, David Ortega of Scottsdale, and Regina Romero of Tucson, and Caris Life Sciences President David Spetzler.
The latest performance data, which was released in April 2022, can be found in this report and a detailed analysis from TEConomy Partners, “Biosciences in Arizona: 2022 Performance Review.” The next data report is scheduled for release in April 2024.